

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)



(10) International Publication Number
WO 2023/192390 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) C07D 487/04 (2006.01)
C07D 471/04 (2006.01) C07D 217/24 (2006.01)

(21) International Application Number:

PCT/US2023/016743

(22) International Filing Date:

29 March 2023 (29.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/325,577 30 March 2022 (30.03.2022) US
63/346,203 26 May 2022 (26.05.2022) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **BAGDASARIAN, Alex L.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **BUCHER, Cyril**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **CRAIG, II, Robert A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **DE VICENTE FIDALGO, Javier**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **ESTRADA, Anthony A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **FOX, Brian M.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **HUFFMAN, Benjamin J.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **LEXA, Katrina W.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **OSIPOV, Maksim**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOUNDS, COMPOSITIONS, AND METHODS

(57) Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.

WO 2023/192390 A1